Medicare Part D coverage · divalproex sodium · RxCUI 1099679

divalproex sodium 250 MG Delayed Release Oral Tablet [Depakote]

Per the CMS 2026 Part D formulary file, divalproex sodium 250 MG Delayed Release Oral Tablet [Depakote] is covered by 2 Medicare Part D plans (0% of enrollable products), averaging Tier 1, with prior authorization required on 0% of covering formularies.

0%
Plan coverage
2
Plans covering
T1
Avg tier
0%
Prior auth required

Verify with CMS →

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.

What the CMS Formulary Data Shows for divalproex sodium 250 MG Delayed Release Oral Tablet [Depakote]

Per the CMS 2026 Part D formulary file, divalproex sodium 250 MG Delayed Release Oral Tablet [Depakote] (RxNorm concept RXCUI 1099679, generic name divalproex sodium) appears on 1 distinct formulary file spanning 2 Medicare Part D plan offerings - 0% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 1, with a cross-plan average of Tier 1.

Real-world access to divalproex sodium 250 MG Delayed Release Oral Tablet [Depakote] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 448,623 Part D beneficiaries filled divalproex sodium 250 MG Delayed Release Oral Tablet [Depakote] in 2023, with total plan-and-beneficiary spending of $141,844,113 and an average per-beneficiary annual cost of $316.18. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry divalproex sodium 250 MG Delayed Release Oral Tablet [Depakote] today.

Coverage Details

Formularies covering
1
Plans covering
2
Coverage rate
0%
Tier range
Tier 1, Preferred Generic
Average tier
Tier 1, Preferred Generic

Restrictions

Prior authorization required
0% of formularies
Step therapy required
0% of formularies
Quantity limits
0% of formularies

2023 Medicare Spending

Beneficiaries
448,623
Total spending
$141,844,113
Avg per beneficiary
$316.18

Tier Distribution Across Plans

2 plans
Tier 1, Preferred Generic

Medicare Advantage Plans (MA-PD) Covering divalproex sodium 250 MG Delayed Release Oral Tablet [Depakote]

2 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
Hamaspik Medicare Choice (HMO D-SNP) Hamaspik, Inc. T1 No $0 NY
Hamaspik Medicare Select (HMO D-SNP) Hamaspik, Inc. T1 No $34.50 NY

Frequently Asked Questions

Is divalproex sodium 250 MG Delayed Release Oral Tablet [Depakote] covered by Medicare Part D?

Yes, divalproex sodium 250 MG Delayed Release Oral Tablet [Depakote] is covered by 2 Medicare Part D plans (0% of all Part D formularies).

What tier is divalproex sodium 250 MG Delayed Release Oral Tablet [Depakote] on Medicare Part D plans?

divalproex sodium 250 MG Delayed Release Oral Tablet [Depakote] averages Tier 1 across Part D plans, ranging from Tier 1 to Tier 1.

Does divalproex sodium 250 MG Delayed Release Oral Tablet [Depakote] require prior authorization?

0% of Part D formularies require prior authorization for divalproex sodium 250 MG Delayed Release Oral Tablet [Depakote]. Step therapy: 0%. Quantity limits: 0%.

How much does Medicare spend on divalproex sodium 250 MG Delayed Release Oral Tablet [Depakote]?

In 2023, total Medicare Part D spending on divalproex sodium 250 MG Delayed Release Oral Tablet [Depakote] was $141,844,113, covering 448,623 beneficiaries. The average spend per beneficiary was $316.18.

Read our methodology - how this data is sourced, computed, and verified.

Nationwide similar Part D drugs

Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.

Closest average formulary tier

Similar prior-authorization rate

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare